Evidence map›Paper›PMID 33620590›Full record

ArticleBreast cancer research and treatment2021

Survival of women diagnosed with breast cancer and who have survived a previous cancer.

Sandi L Pruitt, Hong Zhu, Daniel F Heitjan, Asal Rahimi, Bhumika Maddineni, Anna Tavakkoli, Ethan A Halm, David E Gerber, Danyi Xiong, Caitlin C Murphy

Open access · greenAbstract read
In one paragraph

Article in Breast cancer research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Sandi L PruittDepartment of Population & Data Sciences, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9066, USA. Sandi.Pruitt@utsouthwestern.edu.ORCID http://orcid.org/0000-0002-1007-9176
Hong ZhuDepartment of Population & Data Sciences, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9066, USA.
Daniel F HeitjanDepartment of Population & Data Sciences, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9066, USA.
Asal RahimiHarold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA.
Bhumika MaddineniDepartment of Population & Data Sciences, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9066, USA.
Anna TavakkoliDepartment of Population & Data Sciences, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9066, USA.
Ethan A HalmDepartment of Population & Data Sciences, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9066, USA.
David E GerberDepartment of Population & Data Sciences, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9066, USA.
Danyi XiongDepartment of Population & Data Sciences, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9066, USA.
Caitlin C MurphyDepartment of Population & Data Sciences, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-9066, USA.
Harold C. Simmons Comprehensive Cancer CenterSouthern Methodist University · USSouthwestern Medical Center · USThe University of Texas Southwestern Medical Center · US

Funding

Revisiting Prior Cancer as an Exclusion Criterion for Cancer Clinical TrialsR01CA229834 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI PRUITT, SANDI LEIGH · 2018 to 2023
$2.9M
Development of New Cancer Treatments and InvestigatorsK24CA201543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GERBER, DAVID ERIC · 2016 to 2020
$737k
NCI NIH HHS K24 CA201543NCI NIH HHS K24CA201543NCI NIH HHS R01 CA229834NCI NIH HHS R01CA229834
6 · The paper itself

Abstract

purposeMany women diagnosed with breast cancer have survived previous cancer; yet little is known about the impact of previous cancer on overall and cancer-specific survival.

methodsThis population-based cohort study using SEER-Medicare data included women (age ≥ 66 years) diagnosed with breast cancer between 2005 and 2015. Separately by breast cancer stage, we estimated effect of previous cancer on overall survival using Cox regression and on cause-specific survival using competing risk regression; all survival analyses adjusted for covariates.

resultsOf 138,576 women diagnosed with breast cancer, 8% had a previous cancer of another organ site, most commonly colorectal or uterine cancer or melanoma. Many of these women (46.3%) were diagnosed within 5 years of breast cancer. For all breast cancer stages except IV wherein there was no difference, women with vs. without previous cancer had worse overall survival. This survival disadvantage was driven by deaths due to the previous cancer and other causes. In contrast, women with previous cancer generally had favorable breast-cancer-specific survival, although this varied by stage. Overall survival varied by previous cancer type, timing, and stage; previous lung cancer, cancer diagnosed within 1 year of incident breast cancer, and previous cancer at a distant stage were associated with the worst survival. In contrast, women with a previous melanoma had equivalent overall survival to women without previous cancer.

conclusionWe observed variable impact of previous cancer on overall and breast-cancer-specific survival depending on breast cancer stage at diagnosis and the type, timing, and stage of previous cancer.

Indexed as

Breast NeoplasmsAgedCohort StudiesFemaleHumansMedicareNeoplasm StagingSEER ProgramUnited StatesBreast cancerClinical trial eligibility criteriaMultiple primary malignanciesPrior cancerSurvival

Identifiers

PMID33620590
PMCPMC8318112
OpenAlexW3130951657

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.